Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummet ~90%. See why I changed my rating on SAVA to Sell from Strong Sell.
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting more than 80% before the bell.
What’s left in Cassava after Phase 3 setback for Alzheimer’s drug
Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate simufilam. Read more here.
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies.
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug aimed at treating Alzheimer’s disease failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher,
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin
Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.
Gizmodo5h
A Controversial Alzheimer’s Drug Has Gone Down in Flames
Simufilam, taken as a pill twice a day, failed to show it was better than placebo at slowing down the progression of ...
pharmaphorum12h
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...
Zacks.com on MSN3h
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...
thedeepdive5h
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
MedPage Today3h
Alzheimer's Trials Fail; Blood Test Predicts Tau; Neuroscience Moves to Bluesky
Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...
Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints
Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did ...
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...